prikaz prve stranice dokumenta Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
  Download
PDF 903.4 KB
Scientific paper - Review paper
Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
World Journal of Clinical Cases, 10 (2022), 20; 6759-6768. https://doi.org/10.12998/wjcc.v10.i20.6759
Cigrovski Berković, Maja; Režić, Tanja; Bilić-Ćurčić, Ines; Mrzljak, Anna

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Cigrovski Berković, M., Režić, T., Bilić Ćurčić, I. & Mrzljak, A. (2022). Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. World Journal of Clinical Cases, 10. (20), 6759-6768. doi: 10.12998/wjcc.v10.i20.6759

Cigrovski Berković, Maja, et al. "Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?." World Journal of Clinical Cases, vol. 10, no. 20, 2022, pp. 6759-6768. https://doi.org/10.12998/wjcc.v10.i20.6759

Cigrovski Berković, Maja, Tanja Režić, Ines Bilić Ćurčić and Anna Mrzljak. "Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?." World Journal of Clinical Cases 10, no. 20 (2022): 6759-6768. https://doi.org/10.12998/wjcc.v10.i20.6759

Cigrovski Berković, M., et al. (2022) 'Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?', World Journal of Clinical Cases, 10(20), pp. 6759-6768. doi: 10.12998/wjcc.v10.i20.6759

Cigrovski Berković M, Režić T, Bilić Ćurčić I, Mrzljak A. Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?. World Journal of Clinical Cases [Internet]. 2022 July 16 [cited 2024 November 22];10(20):6759-6768. doi: 10.12998/wjcc.v10.i20.6759

M. Cigrovski Berković, T. Režić, I. Bilić Ćurčić and A. Mrzljak, "Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?", World Journal of Clinical Cases, vol. 10, no. 20, pp. 6759-6768, July 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:322589. [Accessed: 22 November 2024]

Metadata
Title (english)Semaglutide might be a key for breaking the vicious cycle of metabolically associated fatty liver disease spectrum?
AuthorMaja Cigrovski Berković
AuthorTanja Režić
AuthorInes Bilić-Ćurčić
AuthorAnna Mrzljak
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Metabolically associated fatty liver disease (MAFLD) is a liver manifestation of metabolic syndrome potentially related to unfavorable hepatic and extrahepatic outcomes and progression to cirrhosis. Up to date, there are no approved pharmacotherapies for the treatment of MAFLD, so management focused on lifestyle interventions to encourage weight loss, and treatment of coexisting conditions is the only available option. Unfortunately, the aforementioned is often not potent enough to offer reversal or slow down hepatic inflammation and fibrosis. Glucagon-like peptide-1 receptor agonists have a favorable effect on glycemic management and weight loss of patients with type 2 diabetes mellitus and recently published data suggest their potential in MAFLD treatment. In addition, some of the agents have proven cardiovascular and renal benefits in dedicated cardiovascular outcome trials, making them an interesting therapeutic option. In this opinion review, we discuss the role of semaglutide in MAFLD.
Keywords (english)
Languageenglish
Publication typeScientific paper - Review paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleWorld Journal of Clinical Cases
Numberingvol. 10, no. 20, pp. 6759-6768
p-ISSN2307-8960
DOIhttps://doi.org/10.12998/wjcc.v10.i20.6759
URN:NBNurn:nbn:hr:105:322589
Publication2022-07-16
Document URLhttps://www.wjgnet.com/2307-8960/full/v10/i20/6759.htm
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) icon
Created on2023-02-21 08:12:10